2015, Number 614
<< Back Next >>
Rev Med Cos Cen 2015; 72 (614)
Amiloidosis
Tinoco MEF
Language: Spanish
References: 11
Page: 159-162
PDF size: 51.61 Kb.
ABSTRACT
Amyloidosis is a systemic
disorder caused by tissue
deposition of misfolded proteins
that results in progressive
organ damage. There are
several types of amyloidosis,
and they are classified to
their protein precursor.
Each precursor induces a
separate spectrum of organ
involvement. Early diagnosis
and unequivocal identification
of the amyloidogenic protein is
the key to therapy.
REFERENCES
Antonia M. S. Müller, Annette Geibel, Hartmut P. H. Neumann, et al. Primary (AL) Amyloidosis in Plasma Cell Disorders. The Oncologist 2006; 11:824–30.
Berk John L, O’ Regan Anthony, Skinner Martha. Pulmonary and tracheobronchial Amyloidosis. Seminars in Respiratory and Critical Care Medicine 2002; 23: 155–63.
Cibeira M. ª Teresa, Bladé Joan. Amiloidosis primaria: diagnóstico, pronóstico y tratamiento. Haematologica, edición española 2011; 96 (Extra1) 13–17.
Esteve V, Almirall J, et al . Afectación renal en la amiloidosis. Características clínicas, evolución y supervivencia. Nefrología 2006; 26: 212-17.
Falcón B. Afectación Multiorgánica por Amiloidosis Primaria. A propósito de un Caso. Medicrit 2006; 3(2):61–67
Gertz Morie A. Classification and Typing of Amyloid Deposits. Am J Clin Pathol 2004; 121:787–89.
Lachmann HJ, Hawkins PN. Systemic Amyloidosis. Curr Opin Pharmacol 2006; 6:214-220.
Merlini G, Seldin David C, Gertz Morie A. Amyloidosis: Pathogenesis and New Therapeutic Options. J Clin Oncol 2011; 29: 1–10.
Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med wkly 2006;136 : 715–20
Picken Maria M. Amyloidosis- Where Are We Now and Where Are We Heading. Arch Pathol Lab Med 2010; 134: 545–51.
Rodney H. Falk, Simon W. Dubrey. Amyloid Heart Disease. Progress in Cardiovascular Diseases 2010; 52: 347–61.
Full text